Patent · US Active

Use of Akkermansia muciniphila for treating inflammatory conditions

US10537597B2 · kind B2 · utility

5Cited by

0References

15Claims

0Family size

Assignee

SCHWEIZERISCHES FORSCHUNGSINSTITUT FÜR HOCHGEBIRGSKLIMA UND MEDIZIN IN DAVOS · CH

Inventors

Liam O'Mahony · Cork, IE
Cezmi A. Akdis · Davos, CH
David Michalovich · Hertford, GB
Edith M. Hessel · Hertford, GB
James Raymond Brown · Berwyn, US
David N. Mayhew · Collegeville, US
Sorif Uddin · Hertford, GB

Key dates

Filing date	Oct 5, 2016
Grant date	Jan 21, 2020
Priority date	—
Expiry date	Oct 5, 2036

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P29/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to use of Akkermansia muciniphila, a mucin-degrading bacterial species found in the human gut, for treating undesirable inflammatory activity not caused by any metabolic disorder and/or obesity, especially for example undesirable airway inflammatory activity as seen with asthma.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.